ORIGINAL RESEARCH article
Front. Cardiovasc. Med.
Sec. Heart Failure and Transplantation
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1529451
This article is part of the Research TopicOutcome-Oriented Approaches to Arrhythmia and Heart Failure TreatmentView all 8 articles
Serum levels of miR-21, miR-23a, miR-142-5p, and miR-126 in chronic heart failure with reduced ejection fraction: a case-control study
Provisionally accepted- 1Faklutní nemocnice Ostrava, Kardiovaskulární oddělení, Ostrava, Czechia
- 2University of Ostrava, Ostrava, Czechia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
MicroRNAs are small non-coding RNA molecules that do not serve as templates for protein synthesis, but rather function as gene regulators in physiological processes, such as proliferation, differentiation, and apoptosis. These molecules play an important role in cardiology and heart failure. Accumulating evidence, including that from the present study, supports their correlations with the pathophysiology and development of heart failure. These new markers are not just promising as diagnostic tools, but could also provide prognostic information and be targets of future heart failure treatment. Therefore, in the present study, we explored associations between HFrEF the levels of four circulating miRNAs (miR-21-5p, miR-23a-3p, miR-142-5p, and miR-126-3p).
Keywords: Heart Failure and Transplantation David Stejskal: Supervision, Writing -review & editing. Eliska Kufova: Data curation, investigation, Writing -review & editing. Jan Vaclavik: Supervision, Writing -review & editing. Lukáš Evin: Conceptualization, Data curation, methodology, project administration
Received: 16 Nov 2024; Accepted: 18 Apr 2025.
Copyright: © 2025 Evin, Sigutova, Sulc, Kufova, Branny, Vaclavik and Stejskal. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Lukáš Evin, Faklutní nemocnice Ostrava, Kardiovaskulární oddělení, Ostrava, Czechia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.